Latest News
Biomea Fusion, Inc.
- Key facts: Biomea Fusion (BMEA) reports weight loss; analysts keep buys
- Ultragenyx’s second PRV sale; Biomea’s oral GLP-1 data leads to stock slump
- Biomea Fusion reports Phase 1 topline: BMF-650 shows up to 6.1% weight loss, good tolerability
- Biomea Fusion reports positive early weight-loss data for oral GLP-1 drug BMF-650
- Biomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
- Biomea Fusion reports weight loss data from oral GLP-1 trial By Investing.com
- Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
- Biomea Fusion Stock Climbs 7% After-Hours: What's Going On?
- Biomea Fusion to report Phase I trial results Tuesday
- Biomea Fusion to Announce Phase I Results for BMF-650, Its
- Citizens reiterates Biomea Fusion stock rating on menin inhibitor validation
- Biomea Pulls Equity Raise, Trading Dilution Relief For Near-Term Runway Pressure (BMEA)
Headlines from the last 30 days, linking to the original publishers. See all market news →